Medication info
CreaZinc 10mg (Rosuvastatin Calcium)

CreaZinc 10mg (Rosuvastatin Calcium)

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium›10.4mg / 1 tablet
Manufacturer / importer
Youngjin Pharmaceutical Co., Ltd.
Appearance
Pink round film-coated tablets
Packaging
28 tablets/Alu-Alu PTP (7 tablets/Alu-Alu PTP*4)
Approval status
Active

MFDS item code 201400409 · Approved 2014.01.29 · Insurance code 642403840

Summary

Main use
Improvement of dyslipidemia, reduction of cardiovascular disease risk, and inhibition of atherosclerosis progression
Who takes it
Adults · Children
Adult dose
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this drug, and continue it throughout the treatment period. This drug may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20 milligrams daily. 3. Elderly patients: No dosage adjustment is necessary. 4. Patients with renal impairment: No dosage adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering 20mg of this drug to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this drug to patients with active liver disease. 6. Race: Because systemic exposure to this drug is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this drug is contraindicated in some of these patients.
Child dose
2. Pediatric patients with heterozygous familial hypercholesterolemia (ages 10 to 17 years) The usual dosage range is 5 milligrams to 20 milligrams once daily. (There are no clinical data on doses higher than 20 milligrams in pediatric patients.) The dose should be individualized according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or longer. The safety and efficacy in children under 10 years of age have not been established.

Ingredients

Manufacturer
Youngjin Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of dyslipidemia, reduction of cardiovascular disease risk, and inhibition of atherosclerosis progression

  • Hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • arteriosclerosis
  • dysbetalipoproteinemia
  • increased high-sensitivity C-reactive protein
  • hypertension
  • low HDL-cholesterol levels
  • smoking
  • family history of early coronary heart disease
View approved original text

This medication is used in cases of primary hypercholesterolemia, mixed dyslipidemia, and severe lipid disorders such as homozygous familial hypercholesterolemia that are difficult to control with diet and exercise alone. It also helps lower total cholesterol and LDL-cholesterol levels in patients with hypercholesterolemia, thereby slowing the progression of arteriosclerosis. It can be used as an adjunct to diet in pediatric patients aged 10 to 17 years with heterozygous familial hypercholesterolemia. It is also used as an adjunct in the treatment of patients with primary dysbetalipoproteinemia. Additionally, it can reduce the risk of stroke, myocardial infarction, and vascular re-intervention in middle-aged and elderly individuals at high risk for cardiovascular disease. Overall, this medication effectively improves dyslipidemia and the risk of cardiovascular disease.

How to take

Adult dose

1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this drug, and continue it throughout the treatment period. This drug may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20 milligrams daily. 3. Elderly patients: No dosage adjustment is necessary. 4. Patients with renal impairment: No dosage adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering 20mg of this drug to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this drug to patients with active liver disease. 6. Race: Because systemic exposure to this drug is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this drug is contraindicated in some of these patients.

Child dose

2. Pediatric patients with heterozygous familial hypercholesterolemia (ages 10 to 17 years) The usual dosage range is 5 milligrams to 20 milligrams once daily. (There are no clinical data on doses higher than 20 milligrams in pediatric patients.) The dose should be individualized according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or longer. The safety and efficacy in children under 10 years of age have not been established.

Precautions

This medication should not be used in certain patients. For example, it should not be administered to patients who are allergic to any of its components, patients with severely impaired liver function, patients with muscle diseases, or patients with severe renal impairment, as well as women who are pregnant or breastfeeding. Furthermore, patients who consume excessive alcohol or have a history of liver disease should frequently undergo liver function tests before taking this medication. They should inform healthcare providers immediately if they experience any symptoms of muscle pain or weakness, and in severe cases, they may need to discontinue the medication. This medication may increase the risk of muscle damage when taken with certain drugs, so patients must consult with healthcare providers if they are taking other medications. Caution is especially needed when combined with fibrate drugs. Women of childbearing potential should use appropriate contraception, and this medication should not be taken during pregnancy. It is also advisable to avoid this medication while breastfeeding. In case of overdose, there is no specific antidote, and treatment should be based on symptoms, monitoring liver function and muscle enzyme levels. This medication may rarely cause side effects such as headache, dizziness, muscle pain, dyspepsia, skin rash, so if any unusual symptoms persist or worsen, patients should consult healthcare providers. Caution is required as dizziness may occur when driving or operating machinery. Lastly, this medication may have a higher plasma concentration in Asians, so dosage adjustments may be necessary.

Side effects

Hypersensitivity reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, asthenia, polyneuropathy, memory loss, peripheral neuropathy, myasthenia gravis, cough, dyspnea, diarrhea, ocular myasthenia, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, eosinophilia with systemic symptom drug reaction syndrome, lichenoid drug eruption, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal hepatic failure, cognitive impairment, increased ALT, chest pain, muscle cramps, gout, erectile dysfunction, increased AST, numbness, paresthesia, chest discomfort, loss of appetite, abdominal distension, syncope, generalized pain

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent air or moisture from entering and should be kept at room temperature between 1 and 30 degrees Celsius. Storing it this way will help maintain the medication's effectiveness for a longer period.

Appearance and packaging

Appearance

Pink round film-coated tablets

Package unit

28 tablets/Alu-Alu PTP (7 tablets/Alu-Alu PTP*4)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.